BG
Bellevue Group Portfolio holdings
AUM
$4.2B
1-Year Est. Return
54.85%
This Fund
S&P 500
1 Year Est. Return
+54.85%
AUM
$4.2B
AUM Growth
-$1.07B
(-20%)
Holding
195
Top Buys
| 1 | +$203M | |
| 2 | +$156M | |
| 3 | +$146M | |
| 4 |
Amgen
AMGN
|
+$98.7M |
| 5 |
Viridian Therapeutics
VRDN
|
+$70.3M |
Top Sells
| 1 | +$350M | |
| 2 | +$235M | |
| 3 | +$225M | |
| 4 |
RNAM
Avidity Biosciences
RNAM
|
+$190M |
| 5 |
FOLD
Amicus Therapeutics
FOLD
|
+$153M |
Sector Composition
| 1 | Healthcare | 99.74% |
| 2 | Energy | 0.07% |
| 3 | Technology | 0.06% |
| 4 | Financials | 0.03% |
| 5 | Consumer Discretionary | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vertex Pharmaceuticals
VRTX
$108B
| $304M | 7.25% |
681,908
+788
|
|
||
2
argenx
ARGX
$49.9B
| $229M | 5.44% |
313,000
-148,854
|
|
||
3
Regeneron Pharmaceuticals
REGN
$62.3B
| $215M | 5.12% |
278,674
+264,746
|
|
||
4
Scholar Rock
SRRK
$5.45B
| $176M | 4.19% |
3,584,573
-472,019
|
|
||
5
Gilead Sciences
GILD
$159B
| $163M | 3.88% |
1,169,879
+1,117,127
|
|
||
6
Revolution Medicines
RVMD
$32.6B
| $150M | 3.57% |
1,544,456
-3,461,263
|
|
||
7
Ionis Pharmaceuticals
IONS
$12B
| $137M | 3.25% |
1,818,665
-2,983,534
|
|
||
8
Intuitive Surgical
ISRG
$142B
| $132M | 3.14% |
286,654
-35,374
|
|
||
|
9
Viridian Therapeutics
VRDN
$1.76B
| $132M | 3.13% |
6,726,144
+2,367,617
|
|
||
10
Krystal Biotech
KRYS
$8.6B
| $124M | 2.96% |
481,785
+71,462
|
|
||
11
Crinetics Pharmaceuticals
CRNX
$3.45B
| $119M | 2.84% |
3,280,000
+3,275,960
|
|
||
12
Abbott
ABT
$150B
| $118M | 2.81% |
1,151,635
-165,280
|
|
||
13
Nuvalent
NUVL
$7.19B
| $108M | 2.57% |
1,053,268
+15,800
|
|
||
|
14
Amgen
AMGN
$176B
| $104M | 2.47% |
295,358
+276,869
|
|
||
15
Boston Scientific
BSX
$71.1B
| $92M | 2.19% |
1,466,894
-92,712
|
|
||
16
Enliven Therapeutics
ELVN
$2.22B
| $91M | 2.17% |
+2,320,867
|
|
||
17
Immunocore
IMCR
$1.44B
| $84.3M | 2.01% |
2,796,803
|
|
||
18
Medtronic
MDT
$94.8B
| $83M | 1.97% |
957,329
+190,737
|
|
||
19
Alnylam Pharmaceuticals
ALNY
$38.3B
| $77.6M | 1.85% |
234,543
-211,360
|
|
||
20
Relay Therapeutics
RLAY
$3.59B
| $77.6M | 1.85% |
7,795,242
-550,122
|
|
||
21
Stryker
SYK
$113B
| $71.4M | 1.7% |
217,237
-143,340
|
|
||
22
Vaxcyte
PCVX
$6.82B
| $69.2M | 1.65% |
+1,190,697
|
|
||
23
Vera Therapeutics
VERA
$2.29B
| $68.8M | 1.64% |
1,710,771
+12,619
|
|
||
24
Edwards Lifesciences
EW
$50.3B
| $67.2M | 1.6% |
839,451
-203,645
|
|
||
|
DMRA
25
Damora Therapeutics
DMRA
$1.5B
| $59.5M | 1.42% |
+2,298,000
|
|